NEIDL Receives First BSL-4 Pathogens
Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) has begun work with its first Level-4 pathogens, the Ebola and Marburg viruses. Ebola has become a global public health threat, infecting and killing thousands during the 2014 outbreak. There is no available FDA-approved vaccine or therapy for Ebola, or the related Marburg virus. NEIDL researchers are excited to begin work with these pathogens, which could speed the development of remedies.
